

### Disclosures

- Speaker's Bureau for Abbvie, Beiersdorf, Eli Lilly, Janssen, Sanofi Genzyme, Sanofi-Aventis/Regeneron<sup>®</sup>, and Sun Pharma
- Strategic Advisor and Medical Board Member: Arcutis Biotherapeutics, Incyte Labs, Leo Pharma, and Novartis.
- No experimental or investigational use of drugs or devices will be presented.


## **Objectives**


- At the end of this presentation, the participant will be able to:

  - Recognize symptoms and causes of atopic dermatitis.
  - Review the tests and exams necessary for immediate treatment, diagnosis and care.
  - Outline and implement follow-up care.
  - Demonstrate understanding of recent updates on the latest research, trials, and interventions.

3

4





Atopic Dermatitis: Sometimes Obvious, Other Times a Bit Faint





A Brief Introduction to Atopic Dermatitis (AD)

- One of the most common chronic skin disorders in America affecting nearly 30% of people with past history or current AD.
- Prevalence of this condition has risen dramatically during the last three decades.
- Affected 7% of children circa 1960, but 25% today
- 35 million Americans have active AD, and the incidence continues to grow.

7

Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of content or questions.






Atopic Dermatitis Notes from the World		
<ul> <li>world-wide.</li> <li>Often associated with asthma, allergic rhinitis and food allergies</li> <li>Bla for all when the second s</li></ul>	ne strongest genetic risk factor r developing AD is in uropean-descent peoples; but frican-Americans tend to have e most serious cases. ack children have higher risk r asthma and lower risk of lergic rhinitis and food allergy; hile completely opposite for hite children.	







# Sometimes atopy is subtle.















Eczema – Atopic Dermatitis
Greek – Ekzema, from "ekzein," to break out, or boil over
Chronic, pruritic eruption that can appear anywhere on the skin
Associated with scales, fissures, cracking, bleeding and secondary bacterial infections














## **Treatment Paradigms**

- Ultimately, a robust discussion between patient and provider is necessary to learn which plan will result in the greatest safety, efficacy, durability, compliance, and access for the patient.
- The options are overwhelming, but generally come in the broad categories of life-style identification: Topical non-steroidal, topical steroidal, systemic steroidal, rarely used immunosuppressants, oral biologics, or injectable biologics.
- Monotherapy or combinations are possible.

28

Many atopic dermatitis cases only OTC care.	s require attention to detail and
<ul> <li>Cooler, quicker showers</li> <li>Moisturizing cleansers and soaps</li> </ul>	<ul> <li>Use OTC lotions, creams, and ointments within 3 minutes after a shower to trap residual moisture.</li> <li>Look up the "3-minute rule" and other great resources at the National Eczema Association website: <u>https://nationaleczema.org</u></li> </ul>
	29
29	

Many atopic dermatitis cases require attention to detail and only OTC care. (continued)	


30

<ul> <li>Look for products that contain ceramides, oatmeal, filaggrin, dimethicone, petrolatum, glycerin, and humectants.</li> </ul>	<ul> <li>Products that are dye-free, PABA-free, paraben-free, fragrance-free, and are labelled as hypo-allergenic are generally well-tolerated.</li> <li>Patients sometimes appreciate lifestyle changes first.</li> </ul>

30


Many atopic dermatitis cases require attention to detail and only OTC care. (continued)

To prevent eczema flares, the Barrier Enhancement for Eczema Prevention (BEEP) trial did not show that use of OTC moisturizers or bathing prevented the development of eczema in infants, but patients did not worsen when compared to those who avoided moisturizers and bathing.





31

32



The Bleach Bath Controversy	
<ul> <li>On the "pro" side, ¼ cup to forty gallons (59.1 mL–151.4 L) seem to seriously lessen MRSA infections and result in clearer skin.</li> <li>On the "con" side, limited studies, can cause serious irritation to some, and odor is repulsive.</li> </ul>	<ul> <li>The American Academy of Dermatology no longer recommends.</li> <li>The opinion is that some individuals may have low-level staph colonization on their skin excreting irritating toxins, and the diluted bleach may destroy this bacteria.</li> </ul>






## **Irritant Management**

- Swimming hydrates skin.
- Chlorinated pools have been observed as helpful as bleach baths.
- Consider whole house humidifiers: Optimal setting at 40–60% humidity
- Where possible, swimming until the skin has lightly "pruned," or wrinkled, is evidence of maximum water absorption.
- "I went to Florida, and my eczema disappeared!"

38



## Foods as AD Trigger


 Aeroallergens (i.e., dust mites, animal danders, molds and pollens) are classic AD exacerbators.


> ce: NIAID. (2017). Milk. mons.wikimedia.org/wiki/File:Glass of Milk (33657535532).ipg) CC BY 2.0


 Foods as AD exacerbators undergoing intense studies, particularly dairy and sugar.



40











- Topical non-corticosteroidal skin cream (Mimyx<sup>®</sup>)
- Contains palmitamide MEA, lipid improver
- These products require prescription.
- They do not have generic name designations.

44





47

47

Image source: Used with permission from Czerkasii V

Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of content or questions.

**Topical JAK Inhibitor Non-Steroidal Cream (continued)** 

to one-month

May be used anywhere on the body every day for up

axilla, under breasts, groin and inguinal folds, where

• This product is very helpful for periorbital, perioral,

steroids would not be appropriate.


• Apply twice a day for up to one-month.

46

48

- Most common adverse effect burning, itching, swelling at application site.
- Often best to refrigerate the product to use as a cooling agent on sensitive skin.

48



Topical Non-Corticosteroidal Agents: Topical Calcineurin Inhibitors (TCIs)

- Original non-corticosteroidal milestone
- Tacrolimus ointment 0.03%
- Pimecrolimus cream 1%
- Strong safety profile for current length and difficult skin areas


50

• Boxed warning for lack of long-term (4+ years) safety data

50

Topical Non-Corticosteroidal Agents: Topical Calcineurin Inhibitors (TCIs) (continued)

- Back in 2006, TCIs had been given a "boxed" warning of possible malignancies occurring if used regularly over four years.
- No published study has proven the validity of this warning.
- Carefully weigh theoretical risks against benefits.



**Topical Corticosteroids (continued)** 

Atrophy and adrenal suppression

Midpotency is triamcinolone 0.1%.

Adverse effects are both local and systemic.

• Studies do include children as young as age three months.

• Super potent is clobetasol 0.05% or betamethasone 0.1%.

· Good example of a low potency corticosteroid include


hydrocortisone 1% and desonide 0.05% creams.


## **Topical Corticosteroids**

- · Important tool to gain control of AD
- 30 g covers entire skin of adult once
- Seven potency classes based on vasoconstrictor assay.
- The lower the number, the longer the use allowed.
- Creams and ointments preferred as gels have drying glycol base.
- Good clinical skills required to balance potency and adverse effects.

53

55






54

56


When Corticosteroids Attack: Interesting Observations from the Front Line


• Paradoxically, some patients will suffer from inflammatory episodes caused directly from topical corticosteroids. • Multiple supporting studies find that midpotency clocortolone pivalate 0.1% has lowest potential to cause allergic reaction.




58

57





59



## A Sweet Option for Atopic Dermatitis

- Do not use raw honey from the beehive for topical use.
- Recognized for sealing in moisture, well-tolerated
- Excellent wound healing product for cracks and fissures.

Image source: Chiswick Chap. (2013). Long-tongued Amegilla bee on long tube of flower. (https://en.wikipedia.org/wiki/Bee) CC BY-SA 4.0

62



61

The Treatment Landscape: New Non-steroidal Oral Options – Upadacitinib		
<ul> <li>15 mg or 30 mg tablet 1 by mouth every day</li> <li>Treatment for patients ages 12 years and older with moderate to severe atopic dermatitis.</li> </ul>	<ul> <li>JAK inhibitor that requires CBC, CMP, lipid and TB screening prior to initiation and again three months later and then annually.</li> <li>Fast-acting on itching in trials, with results in one day.</li> <li>Significant safety panel includes increased infections, blood clots, stroke, and cardiovascular events.</li> </ul>	
	63	


The Treatment Landscape: New Non-steroidal Oral Options – Abrocitinib		
<ul> <li>100–200 mg tablet one by mouth every day</li> <li>Treatment for patients ages 18 years and older with moderate to severe atopic dermatitis.</li> <li>AK inhibitor that requires CBC, CMP, lipid, Hep B and C and TB screening prior to initiation and then annually or after dose increase.</li> </ul>	<ul> <li>Effective medication in trials for scale and itching</li> <li>Significant safety panel includes increased infections, mortality, malignancies, blood clots, and cardiovascular events.</li> </ul>	
	64	

63

The Treatment Landscape: Injectable Non-steroidal – Dupilumab Targets IL-4 and IL-13			
	<ul> <li>Dupilumab – An FDA approved biologic for atopic dermatitis age</li> </ul>		<ul> <li>Does not require prior labs or testing, nor does it interact with</li> </ul>


The Treatment Landscape: Inj Dupilumab Targets IL-4 and IL	
<ul> <li>Pediatric and adolescent dosing is determined by age and weight.</li> </ul>	<ul> <li>Can be used concurrently with corticosteroids if warranted</li> <li>Highly effective on pruritus</li> </ul>

The Treatment Landscape: Injectable Non-steroidal – Tralokinumab Targets IL-13			
• Most common adverse effects include allergic reactions, cold sores, and inflammation of the cornea.	• Does not require prior labs or testing, nor does it interact with any known disease or medication.		
	67		




## Don't Underestimate the Severity of AD on Quality of Life in Younger Patients?





70

69








## Is it really atopic dermatitis?

- A few classic differentials: Psoriasis, seborrheic dermatitis, allergic urticaria, adverse drug reaction, discoid lupus erythematosus, scabies infestation, or subclinical fungal infection
- Always ask for a robust patient history of condition and treatment.
- Don't be shy to biopsy the site.
- Always be aware of what the condition is not.
- Don't accept what the patient tells you they have: YOU are the professional.

73




# Lichen Simplex Chronicus




- Unusual case of 14-year-old Hispanic male who had an enlarging left areola over one year.
- Stated that it had slight itching, treated with anti-fungal by PCP.
- Punch biopsy revealed severe atopic dermatitis with components of lichen simplex chronicus.
- Class one steroid BID × 2 weeks completely resolved it.

74

73






**Topical Corticosteroids Potency Chart** 

- National Psoriasis Foundation<sup>®</sup> Potency Chart, available at https://www.psoriasis.org/sublearn03 mild potency
- The Dermatologist, available at https://www.hmpgloballearningnetwork.com/site/thederm

These are continuously updated to reflect generic and brand names.

78




## **References (continued)**

- Papapostolou, N., Xepapadaki, P., Gregoriou, S., & Makris, M. (2022). Atopic Dermatitis and Food Allergy: A Complex Interplay What We Know and What We Would Like to Learn. *Journal of clinical medicine*, 11(14), 4222. https://doi.org/10.3390/jcm11144232
- Radi, G., Campanti, A., Diotallevi, F., Martina, E., Marani, A., & Offidani, A. (2022). A Systematic Review of Atopic Dermatitis: The Intriguing Journey Starting from Physiopathology to Treatment, from Laboratory Bench to Bedside. *Biomedicines*, 10(11), 2700. https://doi.org/10.3390/biomedicines10112700
- Wollenberg, A., Werfel, T., Ring, J., Ott, H., Gieler, U., & Weidinger, S. (2023). Atopic Dermatitis in Children and Adults—Diagnosis and Treatment. *Deutsches Arzteblatt international*, 120(13), 224– 234. https://doi.org/10.3238/arztebl.m2023.0011
- Zuberbier, T., Beck, L. A., Bedbrook, A., de Bruin-Weller, M., Bousquet, J., Cork, M., Douladiris, N., Katoh, N., Mortz, C. G., Werfel, T., Wojciech, F., Wollenberg, A., Siemens, K., Stevanovic, K., Worm, M., & AD-ICPs Working Group (2023). Developing integrated care pathways for atopic dermatitis-Challenges and unmet needs. *Clinical and translational allergy*, 13(3), e12236. https://europepmc.org/article/pmc/10040953

Unless noted, image sources are from Shutterstock, used with permission from Colibri Healthcare license.

81



Copyright by Fitzgerald Health Education Associates All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without permission from Fitzgerald Health Education Associates.

Requests for permission to make copies of any part of the work should be mailed to:

82

Fitzgerald Health Education Associates 15 Union Street, Suite 512 Lawrence, MA 01840

82

81

### **Fitzgerald Health Education Associates** Statement of Liability 15 Union Street. Suite 512 • The information in this program has been thoroughly researched and Lawrence, MA 01840 checked for accuracy. However, clinical practice and techniques are a 978.794.8366 Fax-978.794.2455 dynamic process and new information becomes available daily. Prudent Website: fhea.com practice dictates that the clinician consult further sources prior to applying Learning & Testing Center: fhea.com information obtained from this program, whether in printed, visual or verbal form. 👩 Instagram Fitzgerald Health Education Associates disclaims any liability, loss, injury or damage incurred as a consequence, directly or indirectly, of the use https://www.instagram.com/fitzgerald\_health\_ed/ and application of any of the contents of this presentation. Find us on Facebook All websites listed active at the time of publication. www.facebook.com/fitzgeraldhealth Btwitter @npcert 83 84 83 84